Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2013 - 2026)

Ocular Therapeutix's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 30.78% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $4.6 million, a 20.36% increase from a year earlier, with the FY2025 full-year figure at $4.3 million, up 14.18% from the prior year.
• Depreciation & Amortization (CF) rose to $1.3 million in Q1 2026 per OCUL's latest filing, from $1.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q1 2026 and bottomed at $483000.0 in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $951000.0 (2024), against an average of $852176.5.
• Across the five-year window, Depreciation & Amortization (CF) fell 14.31% in 2022 and jumped 95.11% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $491000.0 in 2022, then jumped by 95.11% to $958000.0 in 2023, then slipped by 0.73% to $951000.0 in 2024, then surged by 31.13% to $1.2 million in 2025, then gained by 2.89% to $1.3 million in 2026.
• Per Business Quant, the three latest OCUL Depreciation & Amortization (CF) figures stand at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025).